Free Trial

Analysts Set Immunic, Inc. (NASDAQ:IMUX) PT at $11.60

Immunic logo with Medical background

Shares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have earned a consensus recommendation of "Buy" from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $11.60.

A number of research analysts have issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Immunic in a research report on Thursday, May 1st. D. Boral Capital restated a "buy" rating and set a $10.00 price objective on shares of Immunic in a research note on Wednesday, June 25th. William Blair reissued an "outperform" rating on shares of Immunic in a research note on Friday, May 16th. Wall Street Zen cut shares of Immunic from a "hold" rating to a "sell" rating in a research note on Thursday, March 20th. Finally, B. Riley reissued a "buy" rating and set a $5.00 target price (down previously from $6.00) on shares of Immunic in a research note on Friday, May 23rd.

Check Out Our Latest Analysis on Immunic

Hedge Funds Weigh In On Immunic

Large investors have recently bought and sold shares of the stock. Invesco Ltd. bought a new position in shares of Immunic during the 4th quarter valued at about $37,000. Barclays PLC bought a new position in shares of Immunic during the 4th quarter valued at about $84,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Immunic by 90.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock valued at $205,000 after purchasing an additional 96,894 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Immunic by 279.3% during the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock valued at $226,000 after purchasing an additional 152,726 shares in the last quarter. Finally, Bridgeway Capital Management LLC boosted its position in shares of Immunic by 11.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock valued at $215,000 after purchasing an additional 22,200 shares in the last quarter. Institutional investors and hedge funds own 51.82% of the company's stock.

Immunic Trading Down 2.8%

Immunic stock traded down $0.02 during midday trading on Friday, hitting $0.81. The stock had a trading volume of 663,130 shares, compared to its average volume of 979,124. The business has a fifty day moving average price of $0.85 and a 200 day moving average price of $0.98. Immunic has a 12 month low of $0.56 and a 12 month high of $2.11. The stock has a market cap of $77.21 million, a P/E ratio of -0.66 and a beta of 1.49.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.25) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.25). On average, equities analysts anticipate that Immunic will post -0.94 EPS for the current fiscal year.

Immunic Company Profile

(Get Free Report

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

Further Reading

Analyst Recommendations for Immunic (NASDAQ:IMUX)

Should You Invest $1,000 in Immunic Right Now?

Before you consider Immunic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.

While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

ACT FAST! Congress is Dumping these 3 Stocks
3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines